{"id":509,"date":"2018-09-28T22:14:05","date_gmt":"2018-09-29T03:14:05","guid":{"rendered":"http:\/\/www.creative-peptides.com\/blog\/?p=509"},"modified":"2018-09-28T22:28:25","modified_gmt":"2018-09-29T03:28:25","slug":"alzheimers-disease-and-diabetes-hope-for-inhibitors-against-amyloid-plaques","status":"publish","type":"post","link":"https:\/\/www.creative-peptides.com\/blog\/alzheimers-disease-and-diabetes-hope-for-inhibitors-against-amyloid-plaques\/","title":{"rendered":"Alzheimer&#8217;s disease and diabetes: hope for inhibitors against amyloid plaques"},"content":{"rendered":"<p>Amyloid self-assembly is linked to the pathogenesis of <a href=\"https:\/\/www.creative-peptides.com\/research-areas\/peptides-in-alzheimer-s-disease.html\">Alzheimer\u2019s disease<\/a> (AD) and type\u00a0\u2161\u00a0<a href=\"https:\/\/www.creative-peptides.com\/research-areas\/peptides-in-diabetes.html\">diabetes<\/a> (T2D), Several teams of scientists around the world are working on finding ways to prevent amyloid plaque formation in the human brain, but so far none of the anti-amyloid molecules has reached the clinic. Scientists at the Technical University of Munich (TUM) have now come a little bit closer to a solution:\u00a0They have described a new class of designed macrocyclic peptides (MCIPs)\u00a0that are highly potent inhibitors of amyloid formation. Related research published in the international magazine Angewandte Chemie International Edition.\u00a0In its new study, the team presents macrocyclic peptides, developed as a new class of amyloid inhibitors.\u00a0\u201cWe have discovered an MCIP that is stable in human blood plasma and can also overcome the human blood-brain barrier in an in vitro cell culture model,&#8221; explains Professor Kapurniotu. She adds: \u201cSo far we were \u2018only\u2019\u00a0able to demonstrate these properties in the test tube &#8211; thus further research is necessary. But these are two highly desirable properties for inhibitors of Alzheimer\u2019s amyloid.\u201d<\/p>\n<p><strong><b>The <\/b><\/strong><strong><b>relationship<\/b><\/strong><strong><b>\u00a0between <\/b><\/strong><strong><b>\u03b2-amyloid<\/b><\/strong><strong><b>\u00a0and AD, TDM2<\/b><\/strong><\/p>\n<p><strong><b>\u00a0<\/b><\/strong>Many lines of evidence support that \u03b2-amyloid (A\u03b2) peptides play an important role in Alzheimer\u2019s disease (AD), the most common cause of dementia.\u00a0A\u03b2 peptides are generated through the proteolytic cleavage of amyloid precursor protein (APP), a transmembrane protein, by enzyme complexes \u03b1, \u03b2 and \u03b3-secretases. Alzheimer\u2019s disease (AD), which is the most common age-dependent neurodegenerative disease, is characterized by the presence of amyloid deposition, neurofibrillary tangles, progressive loss of synapses, and severe cognitive dysfunction. Excessive accumulation of \u03b2-amyloid peptides (A\u03b2) is a widely recognized early event that leads to the development of AD pathologies, including impairments in synaptic functions at various sites.\u00a0Type II diabetes mellitus (TDM2) is associated with an increased risk of cognitive dysfunction and dementia.\u00a0Insulin also regulates the metabolism of \u03b2-amyloid and tau, the building blocks of amyloid plaques and neurofibrillary tangles, the neuropathological hallmarks of Alzheimer&#8217;s disease.<\/p>\n<p><strong><b>Conclusion<\/b><\/strong><\/p>\n<p>In the more than 20 years that the amyloid hypothesis has been formally articulated, a wealth of studies from many laboratories worldwide has supported its broad outlines. The development of anti-A\u03b2\u00a0therapeutics remains a rational approach to treating AD\u00a0and TDM2, based on current understanding\u00a0and research\u00a0of the earliest features of this disease.\u00a0Disease treatment strategies require more research. When starting your project, you may have certain expectations in mind and know exactly the route that you want your project to take. Remember that the Creative peptides\u00a0has technical expertise and has probably seen a project like yours several times previously so take their advice on board.<\/p>\n<p>References:<\/p>\n<ol>\n<li>Spanopoulou, A., Heidrich, L., Chen, H. R., Frost, C., Hrle, D., Malideli, E&amp; Rammes, G. (2018). Designed Macrocyclic Peptides as Nanomolar Amyloid Inhibitors Based on Minimal Recognition Elements.\u00a0<em><i>Angewandte Chemie International Edition<\/i><\/em>.<\/li>\n<li>Gouras, G. K., Olsson, T. T., &amp; Hansson, O. (2015). \u03b2-amyloid Peptides and Amyloid Plaques in Alzheimer\u2019s Disease.\u00a0<em><i>Neurotherapeutics<\/i><\/em>,\u00a0<em><i>12<\/i><\/em>(1), 3-11.<\/li>\n<li>Hardy, J., &amp; Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer&#8217;s disease: progress and problems on the road to therapeutics.\u00a0<em><i>science<\/i><\/em>,\u00a0<em><i>297<\/i><\/em>(5580), 353-356.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Amyloid self-assembly is linked to the pathogenesis of Alzheimer\u2019s disease (AD) and type\u00a0\u2161\u00a0diabetes (T2D), Several teams of scientists around the world are working on finding ways to prevent amyloid plaque &#8230;<\/p>\n","protected":false},"author":1,"featured_media":514,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[75],"tags":[],"_links":{"self":[{"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/posts\/509"}],"collection":[{"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/comments?post=509"}],"version-history":[{"count":2,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/posts\/509\/revisions"}],"predecessor-version":[{"id":515,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/posts\/509\/revisions\/515"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/media\/514"}],"wp:attachment":[{"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/media?parent=509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/categories?post=509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/tags?post=509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}